Cardiomyocyte MEA Data Analysis (CardioMDA) – A Novel Field Potential Data Analysis Software for Pluripotent Stem Cell Derived Cardiomyocytes by Pradhapan, Paruti et al.
 
 
This document has been downloaded from  





The permanent address of the publication is http://urn.fi/URN:NBN:fi:uta-
201310241513  
 
Author(s):  Pradhapan, Paruti; Kuusela, Jukka; Viik, Jari; Aalto-Setälä, Katriina; Hyttinen, Jari 
Title:  
Cardiomyocyte MEA Data Analysis (CardioMDA) – A Novel Field 
Potential Data Analysis Software for Pluripotent Stem Cell Derived 
Cardiomyocytes 
Year:  2013 
Journal 
Title:  Plos ONE 
Vol and 
number:  8 : 9  
Pages:  1-11 
ISSN:  1932-6203 
Discipline:  Medical biotechnology 
School 
/Other Unit:  Institute of Biomedical Technology 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1371/journal.pone.0073637  
URN:  URN:NBN:fi:uta-201310241513 
URL:  http://dx.doi.org/10.1371/journal.pone.0073637  
 
 
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
Cardiomyocyte MEA Data Analysis (CardioMDA) – A
Novel Field Potential Data Analysis Software for
Pluripotent Stem Cell Derived Cardiomyocytes
Paruthi Pradhapan1,3., Jukka Kuusela2,3., Jari Viik1,3, Katriina Aalto-Seta¨la¨2,3,4*, Jari Hyttinen1,3*
1Department of Electronics and Communications Engineering, Tampere University of Technology, Tampere, Finland, 2 Institute of Biomedical Technology, University of
Tampere, Tampere, Finland, 3 BioMediTech, Tampere, Finland, 4HeartCenter, TampereUniversityHospital, Tampere, Finland
Abstract
Cardiac safety pharmacology requires in-vitro testing of all drug candidates before clinical trials in order to ensure they are
screened for cardio-toxic effects which may result in severe arrhythmias. Micro-electrode arrays (MEA) serve as a
complement to current in-vitro methods for drug safety testing. However, MEA recordings produce huge volumes of data
and manual analysis forms a bottleneck for high-throughput screening. To overcome this issue, we have developed an
offline, semi-automatic data analysis software, ‘Cardiomyocyte MEA Data Analysis (CardioMDA)’, equipped with correlation
analysis and ensemble averaging techniques to improve the accuracy, reliability and throughput rate of analysing human
pluripotent stem cell derived cardiomyocyte (CM) field potentials. With the program, true field potential and
arrhythmogenic complexes can be distinguished from one another. The averaged field potential complexes, analysed
using our software to determine the field potential duration, were compared with the analogous values obtained from
manual analysis. The reliability of the correlation analysis algorithm, evaluated using various arrhythmogenic and
morphology changing signals, revealed a mean sensitivity and specificity of 99.27% and 94.49% respectively, in determining
true field potential complexes. The field potential duration of the averaged waveforms corresponded well to the manually
analysed data, thus demonstrating the reliability of the software. The software has also the capability to create overlay plots
for signals recorded under different drug concentrations in order to visualize and compare the magnitude of response on
different ion channels as a result of drug treatment. Our novel field potential analysis platform will facilitate the analysis of
CM MEA signals in semi-automated way and provide a reliable means of efficient and swift analysis for cardiomyocyte drug
or disease model studies.
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Introduction
Cardiac safety pharmacology testing is used to identify drug-
induced complications, such as prolongation of the QT interval,
due to several cardiac and non-cardiac drugs. The prolongation of
QT-interval has been linked with the occurrence of severe
arrhythmias which have often proved to be fatal [1] [2]. As a
result of cardio-toxic effects, many drugs have been withdrawn
from the market or advanced stages of preclinical drug develop-
ment. To avoid such undesired consequences regulatory author-
ities such as Food and Drug Administration (FDA) and European
Medicines Agency (EMEA) require in vitro testing for all drug
candidates to reveal potential risks of QT-interval prolongation
before clinical experiments.
In vitro preclinical testings have shown to reduce cost, time and
failed clinical trials [3] [4]. Multi-electrode arrays (MEAs) can be
used to study cellular electrophysiology of cardiomyocytes (CMs) at
the cell population level. The use of MEA is a well-accepted
technique for recording electrical signals from excitable cells and
tissues with high spatial and temporal resolution [5] [6]. The cell
culture dish with MEA has surface embedded electrodes that can
sense changes in the electrical activity of the cells. The signals
recorded are extracellular field potentials generated by the CMs [7].
Earlier studies have shown that the extracellular field potential
recordings can be used to determine characteristics of the cardiac
action potential such as the field potential duration (FPD), which
correlates closely with the QT-interval in the electrocardiogram
(ECG) [8] [9]. As a result, the MEA platform has been used
extensively in the study of human pluripotent stem cell (hPSC)
derived CMs [10–13] and in vitro electrophysiological drug testing
[14–17].
MEA recordings can generate large volumes of data as several
electrodes from each individual recording contain useful informa-
tion. Traditionally, data from MEA recordings have been analysed
manually which is labour-intensive, slow and often user depen-
dent. Manual data analysis forms a bottleneck for high-throughput
screening and can sometimes be unreliable due to poor quality of
the signals. Commercial software for CM MEA data analysis
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(Cardio2D+, Multichannel Systems Reutlingen, Germany),generic
software (e.g. Spike2 – Cambridge electronic design, Labchart –
AdInstruments, ClampFit – Molecular devices) that can be utilized
for cardiomyocyte MEA data analysis or other assay services
(QTempo, Reprocell, Japan) are currently available for cardio
toxicity testing but most of them suffer certain drawbacks. For
example, the Cardio2D+ analysis software allows averaging of
multiple field potential complexes for data analysis but requires its
own specialized recording software. Moreover, it requires data to
be in its native format, thereby rendering data from other sources
incompetent. MATLAB (Mathworks, Inc., Natick, Massachusetts,
United States) based programs and some custom-made MATLAB
Figure 1. Flowchart representing the workflow of CardioMDA. On execution of the program, the graphical user interface (GUI) opens up. In
phase I, the user loads the data that is to be analysed. The program automatically pre-processes to remove noise and after peak detection, the user is
prompted to select a template for analysis. During correlation analysis, the program checks for field potential complexes whose correlation coefficient
satisfies the user-defined correlation factor and produces an average waveform. In phase II, the program allows the user to define the onset and
offset, either automatically using the built-in algorithms, or manually by the user. The process is repeated for upto ten signals and the field potential
duration and other parameters are compared. The results can be saved for future reference.
doi:10.1371/journal.pone.0073637.g001
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toolboxes [19–22] have been developed for signal analysis but
these programs require MATLAB to run and, with the exception
of MEA-tools, they are not available in open source. MEA
recordings from three-dimensional CM aggregates exhibit varia-
tion in signal amplitude and shape due to distance and orientation
between the source and the electrode surface [18]. As a result, the
signal-to-noise ratio (SNR), depicting the quality of the recorded
signals, may vary between different cardiac cell populations.
Moreover, the detection of sporadically occurring arrhythmic
complexes also poses a challenge to researchers, who often have to
screen large volumes of data to identify such morphology changes
as a result of drug treatment.
The aim of the study was to develop a field potential analysis
software platform to facilitate evaluation of drug response in CMs and
compare the FPD prolongation against different drug concentrations.
Here, we present our offline, semi-automatic software ‘Cardiomyo-
cyte MEA Data Analysis (CardioMDA)’, which is designed to
improve the accuracy, reliability and throughput rate for drug
screening and analysis. We demonstrate the usability and capability
of the software using human induced pluripotent stem cell (iPS cell)
derived CMs. The software is validated by calculating the mean
sensitivity and specificity of true field potential detection using several
arrhythmogenic and morphology changing signals. In addition, the
software based analysis outcomes are compared to manual analysis
results to establish the reliability of the analysis software.
Material and Methods
Human iPS cell generation, cell culture and cardiac
differentiation
The study was approved by the ethical committee of Pirkanmaa
Hospital District (R08070) and written informed consent was
obtained from all the participants. Human iPS cells were
generated as described earlier [23]. Control human iPS cells
(UTA.04602.WT) [24] were cultured in knockout serum-replace-
ment (KSR) medium using mouse embryonic fibroblasts (MEF;
Millipore, Billerica, MA) as feeders. The components of KSR
medium are: knockout (KO)-DMEM (Invitrogen) containing 20%
KO-serum replacement (KO-SR, Invitrogen), nonessential amino
acids (NEAA), Glutamax, penicillin/streptomycin, 0.1 mM 2-
mercaptoethanol and 4 ng/ml fibroblast growth factor 2 (FGF2)
(bFGF, R&D Systems Inc., Minneapolis, MN, USA). The medium
was refreshed three times a week and the human iPS cells were
passaged weekly using collagenase IV (Invitrogen). Human iPS
cells were differentiated into CMs in co-culture with mouse
visceral endoderm-like END-2 cells [25] (a kind gift from Christine
Mummery, Hubrecht Institute, Utrecht, The Netherlands). The
END-2 differentiation method has been described elsewhere [25].
In vitro field potential recordings and data analysis
Beating aggregates of CMs were manually dissected and plated
on 6-well MEAs (6-well MEA 200/30iR-Ti-tcr, Multichannel
Systems, Reutlingen, Germany), which were first coated with fetal
bovine serum (FBS, Invitrogen) for 30 minutes at room temper-
ature and then with 0.1% gelatine (Sigma Aldrich) for 1 hour at
room temperature. The CM aggregates were cultured in EB-
medium: KO-DMEM with 20% FBS, NEAA, Glutamax and
penicillin/streptomycin. The field potentials of spontaneously
beating aggregates of CMs were recorded at +37uC with the MEA
platform (MEA1060-Inv-BC, Multichannel Systems, Reutlingen,
Germany) using 20 kHz sampling frequency and MC_Rack
(Multichannel Systems, Reutlingen, Germany) software. The
MEAs were covered with gas-permeable membranes (ALA
MEA-SHEET, ALA Scientific) during recordings. For drug tests,
Figure 2. Screenshot of the graphical user interface for CardioMDA. The screenshot presents the Load panel of the CardioMDA software
with its interactive interface options and basic signal information. Once the template has been selected, the user then moves to the Average panel to
set and execute the correlation analysis. Compare, Analyze and Statistics panel are used to measure the field potential duration and compare it with
other drug concentrations.
doi:10.1371/journal.pone.0073637.g002
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s
the CMs were cultured in 5% FBS containing EB medium. The
hERG channel blocker E-4031 (Sigma Aldrich), Sotalol (Sigma
Aldrich), JNJ303 (Tocris Bioscience) and Esmolol (Brevibloc,
Baxter) were diluted in culture medium for a concentration range
of 100–700 nM, 1.6–19.4 mM, 1–7.5 mM and 84–168 mM
respectively. Baseline conditions as well as drug effects were
recorded for 2 minutes after a 2 minute drug wash-in. The FPDs
and beating rates from the recordings were analysed offline by
ClampFit (Molecular Devices) and by our CardioMDA software
for comparison studies. Twenty five field potential complexes for
each individual recording from the raw data were analysed
manually and the mean FPDs were compared to the correspond-
ing averaged signal FPDs obtained using CardioMDA.
System requirements and data format
CardioMDA is available in the executable file format and
requires about 6 Mb of free hard disk space. The program will run
on any system running Matlab 7.13 (The MathWorks Inc., Natick,
Massachusetts, United States) or a system installed with the
Matlab Compiler Runtime version 7.16 (The MathWorks Inc.,
Natick, Massachusetts, United States). The current version has
been tested on Matlab R2011b running on Microsoft Windows 7
(Microsoft Inc., Seattle, United States) platform and is available in
both 32-BIT and 64-BIT file formats.
The signals of CMs recorded using MEA1060-Inv-BC amplifier
(Multichannel Systems Reutlingen, Germany) or similar, are in the
native. mcd format. The current version of the program will only
support files in the ASCII format, converted using the MC_Da-
taTool (Multichannel Systems, Reutlingen, Germany) software.
Figure 3. Unstable signal morphology as a result of drug treatment. Signal showing changing morphology as a result of drug treatment.
Field potential complex I and field potential complex II have different signal properties in terms of amplitude and duration, thereby accentuating the
need for correlation analysis.
doi:10.1371/journal.pone.0073637.g003
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Signals from multiple electrodes can be recorded on a single
ASCII file with header lines containing information on the
available electrodes, which is essential during analysis.
Program description
The flowchart of the CardioMDA module is shown in Fig. 1.
On execution of the program and opening of the graphical user
interface (GUI), the first step involves importing data that needs to
be examined. This can be performed at two different stages: Phase
I – for correlation analysis and averaging or Phase II – for
evaluation of FPDs.
In Phase I, raw signals are imported for analysis and the
available electrodes are indicated on the program interface to
assist the user in choosing electrodes that needs to be analysed.
After pre-processing and peak detection, a template, which is used
as a comparison standard all detected field potential complexes, is
selected for cross correlation analysis and ensemble averaging. In
phase II, signals that have already undergone Phase I processing
are imported for in-depth analysis and quantization of FPD
prolongation due to drug injection. Up to ten different signals can
be analysed simultaneously in the phase II stage.
Pre-processing. Low-pass Butterworth filter of order 5 with
a cut-off frequency of 200 Hz is implemented to attenuate noise
that may affect signal quality. For correlation analysis, it is
essential that all the field potential complexes in the signal are
detected accurately. A simple window-threshold based technique
has been adapted for our software.
Correlation analysis. Correlation analysis plays an integral
role in identifying arrhythmogenic or morphology changing
signals as a result of drug treatment. Correlation analysis is
performed to identify field potential complexes that closely
resemble the selected template [26] [27]. In our program, the
template can either be chosen as default, which denotes the
selection of the field potential complex positioned at the centre of
the total recording duration, or manually, allowing the user to
select a field potential complex that best reflects the effect of drug
on the cells. The cross correlation function then measures the
degree of similarity between the chosen template and all detected
field potential complexes. The correlation coefficient is computed
as the sum of the products of corresponding pairs of points from
the two complexes within a specified time window. The formula
for cross correlation is represented as:
Figure 4. Comparison of correlation analysis results with different values of correlation factor. An illustration of the correlation analysis
procedure for morphology changing (top row) and arrhythmogenic signals showing premature activation (bottom row) for different correlation
factors is shown. The field potential complexes in green have a correlation coefficient greater than correlation factor and are identified as true field
potential complexes (accepted for averaging) whereas those in red are identified as true negatives (rejected for averaging). The black line presents
the morphology of averaged signal. In both cases, it can be seen that for lower value of correlation factor (0.93), a number of false positives occur,
causing a significant change in the morphology of the averaged waveform. From the bottom row, it can be seen that a higher correlation factor (0.98)
is more accurate in identifying the true field potential complexes.
doi:10.1371/journal.pone.0073637.g004
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Where N represents the number of samples in the time window, n
is the overlap factor and x1 and x2 are the signals. The factor 1/N
is used to normalize the results based on the number of sample
points. The value of c1,2 determines the level of similarity between
the two signals. A user-defined correlation factor (CF) determines
the level of similarity required to pool the data for averaging. All
the field potential complexes whose correlation coefficients are
equal or greater than the pre-defined CF are ensemble averaged to
produce the representative field potential complex. The resulting
average waveform has been shown to represent a general
morphology of the field potential complexes present in the raw
signal [28] [29].
Field potential duration onset and offset detection. The
detection of the beginning and end-point of the FPD (onset and
offset points, respectively) is essential for reliable data analysis.
Here, automatic onset detection was formulated based on
amplitude changes at every sample point in the signal with respect
to subsequent amplitudes within a particular time frame.
Trapezium’s area method (TRA) proposed by Va´zquez-Seisdedo-
setal.[30] to identify the end of T wave is adapted for offset
detection and is based on calculation of successive areas of a
rectangular trapezium with three fixed vertices and one moving
point vertex. The moving point vertex shifts from detected valley-
Table 1. Cross correlation results for normal, arrhythmogenic and morphology changing signals with different values of
correlation factors.
MEA recording from hiPSC-CMs CF TP FP TN FN PPV Sensitivity Specificity
Normal signal
Baseline 0.88 136 2 0 0 98.55% 100% –
0.93 136 2 0 0 98.55% 100% –
0.98 136 0 2 0 100% 100% 100%
Morphology changing signal
E-4031 400 nM + Esmolol – 84 mM 0.88 38 20 0 0 65.52% 100% –
0.93 38 6 14 0 86.36% 100% 70%
0.98 38 2 18 0 95% 100% 90%
Arrhythmogenic signal
E-4031 – 700 nM 0.88 59 27 0 0 68.61% 100% –
0.93 59 7 20 0 89.39% 100% 74.07%
0.98 59 3 24 0 95.16% 100% 88.89%
CF-Correlation factor, TP-True positive, FP-False positive, TN-True negative, FN-False negative, PPV-Positive predictive value.
From the table, it can be seen that PPV and specificity show significant improvement with an increase in CF. Experimental results have shown that CF between the
ranges of 0.96–0.98 produce consistent results.
doi:10.1371/journal.pone.0073637.t001
Table 2. Statistical measure of performance in accurately detecting true field potential complexes in arrhythmogenic and
morphology changing signals using cross correlation with CF = 0.98.
MEA recording from hiPSC-CMs TP FP TN FN PPV Sensitivity Specificity
Arrhythmogenic signals
E-4031 – 10 nM 141 0 9 0 100% 100% 100%
E-4031 – 100 nM 281 3 24 2 98.94% 99.34% 88.89%
E-4031 – 700 nM 59 3 24 0 95.16% 100% 88.89%
E-4031 – 700 nM 22 2 51 0 91.67% 100% 96.23%
Morphology changing signals
E-4031 400 nM + Esmolol 84 mM 38 2 18 0 95% 100% 90%
E-4031 – 700 nM + Esmolol 84 mM 37 2 71 2 94.87% 94.87% 97.26%
E-4031 – 700 nM + Esmolol 168 mM 37 1 167 0 97.36% 100% 99.41%
E-4031 – 1000 nM+ Esmolol 168 uM 44 1 20 0 97.78% 100% 95.24%
Average: 96.35% 99.27% 94.49%
CF-Correlation factor, TP-True positive, FP-False positive, TN-True negative, FN-False negative, PPV-Positive predictive value.
Sensitivity, specificity and PPV show consistent results for different datasets of arrhythmogenic and morphology changing signals. Results indicate that the correlation
analysis is highly sensitive and specific in detecting field potential complexes. A mean PPV of 96.35% indicates that true field potential complexes are detected with a
high degree of accuracy, irrespective of the type of signal being analysed.
doi:10.1371/journal.pone.0073637.t002
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point after the activation peak to the last available sample point
while the total trapezium area is computed and the point at which
the area is maximum can be defined as the offset. From the onset
and offset points, the program computes the FPD, corrected FPD
(cFPD) using Bazett’s equation and the area under the curve.
Bazett’s equation is used to normalize FPD measurements to the
beating rate of contracting cardiac cells [15].
Graphical User Interface (GUI)
The interface is divided into five panels: The Load panel for data
and signal information, Average panel for the correlation analysis,
Analyze panel for onset and offset detection, Compare and Statistics
panels to study the properties and differences between drug
concentrations. Each panel has its own set of icon buttons to
perform different functions. The tool tip strings describe the basic
function of each user interface button, thereby assisting new users
for ease of operation. All analysis results and overlay plots can be
saved for future reference. Fig. 2 shows the screenshot of
CardioMDA GUI with the load panel on display.
Statistical analysis
Sensitivity and specificity analysis are used to evaluate the
performance of the correlation analysis technique used in this
study. In order to define these measures, it is essential to have a
fundamental understanding of the following terms: TP – number
of true positives (field potential complex resembles the selected
template and the correlation coefficient is equal or greater than
CF); FP – number of false positives (field potential complex does
not resemble the template selected but the correlation coefficient is
greater than or equal to CF); TN – number of true negatives (field
potential complex does not resemble the template and the
correlation coefficient is lesser than CF); and FN – number of
false negatives (field potential complex resembles the template but
the correlation coefficient is lesser than CF). Sensitivity is the
proportion of field potential complexes which satisfy the CF and





Specificity is the proportion of complexes which do not satisfy
the CF criterion and are correctly classified as dissimilar to the
template.
Figure 5. Illustration of smoothing effect after ensemble averaging. N denotes the number of ensembles used for averaging. The resulting
waveform from ensemble averaging is smoother when the number of ensembles being averaged is higher.
doi:10.1371/journal.pone.0073637.g005
Table 3. Field potential duration prolongation with increased hERG channel blocker E-4031 drug concentrations.
Manual analysis of raw data Analysis using CardioMDA
Mean ± S.D. Mean
E-4031 drug concentration FPD (ms) BR (bpm) FPD (ms) BR (bpm)
Baseline 300.3468.81 12862.4 306 127
E-4031–100 nM 306.0569.84 13562.5 313.5 134
E-4031–300 nM 329.57610.30 13062.0 331.2 129
E-4031–500 nM 360.50610.7 12261.2 364.1 122
E-4031–700 nM 410.93614.0 11360.86 423.9 112
Abbreviations: FPD- field potential duration, BR-beating rate.
Mean and S.D. of field potential durations from manually analysed field potential complexes (n = 25) were compared to those of corresponding averaged signals from
CardioMDA in a drug dataset depicting the effect of E-4031 on human iPSC-derived CMs. The field potential duration rises as a result of increasing drug concentration.
From the results obtained using our software, it can be seen that the changes in field potential duration correspond well to values obtained from manual analysis.
doi:10.1371/journal.pone.0073637.t003
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The positive predictive value (PPV) signifies the proportion of
field potential complexes with a positive CF which actually





Cardiac drug safety screening is of big concern in the
pharmaceutical industry. The withdrawal of several unsafe drugs
from the market accentuates the need for systemic screening
during the drug development phase. Analysing methods include
organ models such as Langendorff heart and cell models such as
conventional electrophysiology with patch clamp systems on CM
and heterologous expression systems [8]. Traditionally, the patch
clamp technique has been regarded as the golden standard to
determine electrical properties of the cells but it needs highly
skilled operator and is time intensive, therefore making it
unsuitable for high-throughput screening [4]. Moreover, currently
available methods are not fully adequate to reveal adverse
repolarisation effects of potential new drug candidates [31] [32].
The MEA platform together with hPSC-derived CMs may serve
as a complement to current methods for screening new drugs. The
recent hardware development in the MEA-technology has led to
the capability of acquiring large volumes of data. For example,
hardware from Multichannel Systems (MCS, Germany) allows
recording of electrical activity from up to 252 electrodes (USB-
MEA256) and up to nine different cell populations (256–9 well
MEA) at once. Although the actual MEA recordings are relatively
simple and time-efficient, the development of software for data
analysis has fallen behind. The manual data analysis is demanding
and has been a bottleneck for high-throughput screenings. To
perform these screening tests in a time efficient and systemic
manner, we formulated the CardioMDA that is intended to be
useful for researchers working with CMs. The software is
interactive and requires no specific programming knowledge as
all the functions are available on the intuitive graphical user
interface.
Figure 7. Overlay plot showing the effect of sotalol on field
potential duration and signal shape. As a result of drug treatment,
the repolarisation wave peak, which corresponds ECG T-wave, is
prolonged due to increasing concentration of Sotalol. However, the
offset point of field potential duration is similar between different
Sotalol concentrations.
doi:10.1371/journal.pone.0073637.g007
Figure 8. Overlay plot showing effect of IKs-blocker JNJ303 on
field potential duration and signal shape. Similar to Sotalol,
JNJ303 prolongs the repolarisation wave peak but the field potential
duration offset point is similar between different JNJ303 concentrations.
doi:10.1371/journal.pone.0073637.g008
Figure 6. Overlay plot showing the effect of hERG potassium
channel blocker E-4031 on field potential duration. As a result of
E-4031 treatment, the increase in field potential duration is dependent
on the concentration of the drug. The effect of the drug can most
prominently be seen at the repolarisation wave peak as a change of
signal amplitude and the prolongation of the repolarisation wave peak
compared to baseline signal. The effect of the drug can also be seen as
a prolongation of the offset point at the end of the field potential cycle.
doi:10.1371/journal.pone.0073637.g006
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Correlation analysis and ensemble averaging
Although several studies have successfully adapted the correla-
tion technique for ECG beat detection and location of fiducial
points (landmarks of ECG such as onset of P wave) [27] [33] [34],
the correlation algorithm has not been tested on electrical activity
recorded from CMs plated on MEA. The significance of using this
method lies in its ability to accurately and consistently determine
true field potential complexes in morphology changing or
arrhythmogenic signals. Likewise, by choosing an arrhythmogenic
field potential complex as template, the incidence of arrhythmo-
genic behaviour in the recording can be determined. This greatly
simplifies the task of manually screening the datasets to identify
arrhythmogenic behaviour. Fig. 3 shows an example of how the
drug affects the morphology of the signal and the importance of
choosing an appropriate template for the analysis.
To evaluate the results of correlation analysis, stable, morphol-
ogy changing and arrhythmogenic signals were examined and
were subject to analysis with different values of correlation factors
(CFs). Arrhythmogenic signals showing premature activation were
obtained by applying a hERG potassium channel blocking drug E-
4031 to the CM aggregates. Morphology changing signals (see
example in Fig. 3) were obtained when E-4031 challenged CM
aggregates were treated with b-blocker Esmolol. The same
template was chosen each time for different signal set (normal,
morphology changing and arrhythmogenic signals) and analysed
using different CF values. Fig. 4 shows how the identification of
true field potential complexes is affected by CF. Sensitivity and
specificity of determining true field potential complexes were
calculated for these datasets, as shown in Table 1, to ensure the
results are consistent. It can be observed that with increasing CF,
there is a significant increase in positive predicted value (PPV) and
specificity, irrespective of the type of signal being analysed.
To ensure the algorithm produces consistent results, analysis
was performed on multiple datasets. Table 2 presents the outcome
from this study. The mean sensitivity and specificity for accurately
detecting true field potential complexes with CF set at 0.98 were
99.27% and 94.49%, respectively. The algorithm also exhibited a
mean PPV of 96.35%, which indicates that the detection
algorithm is accurate. However, extremely high CF may render
a very rigid selection criterion, greatly reducing the number of
ensembles available for averaging. Therefore, the CF should be
chosen prudently such that a right balance is achieved between
statistical performances and averaging. From experiments, it was
determined that CF values in the range of 0.96–0.98 were optimal
for correlation analysis. However, the user needs to consider the
degree of similarity that needs to be attained between the selected
template and field potential complexes to satisfy the selection
criterion. In some studies, the signal shape may prove to be trivial
and therefore a less stringent CF will suffice the study protocol.
Cross correlation has been used extensively for beat detection
and averaging ECG waveforms to remove artefacts [35–36].
Variations from the cross correlation algorithms in ECG have also
been successful and computationally efficient [37]. However, to
our knowledge these tools have not been used in MEA analysis.
The correlation interval is an important parameter to consider
while making correlation analysis. If the interval is too large, the
components of the adjacent field potential complex maybe
considered for correlation whereas, on the other hand, if the
interval is too small, the desired portions of the signal may not be
considered [27]. In order to ensure that such discrepancies are
avoided, we chose the smallest beat-beat duration as the
correlation interval.
Ensemble averaging has been shown to be effective for noise
attenuation [38]. Higher number of ensembles produces a better
SNR which conceives a smooth average of the field potential
complexes. For ensemble averaging, precise synchronization of
field potential complexes is vital. The averaging accuracy depends
on the accurate definition of fiducial points in the field potential
complexes and the constant time interval between the point and
signal being analyzed. In our study, the normal field potential
complexes were aligned with the window centred on the detected
QRS-like complex as the variability between beats was found to be
minimum. The smallest beat-to-beat interval was chosen as the
window length for the alignment. The number of ensembles
recorded during a period of 2 minutes from each cardiac
aggregate varied across different recordings. As illustrated in
Fig. 5, it was observed that the signal was smoother as the number
of ensembles increased. However, inaccurate alignment of the
ensembles could cause a low pass filtering effect [39] which might
suppress the high frequency components during averaging. Laciar
et al. [40] have shown that an alignment error of 1 millisecond
(ms) corresponds to a low pass filter of cut-off frequency 133 Hz for
ECG measurements. In order to avoid filtering effects of ensemble
averaging, it is ideal that the alignment errors are less than 0.5 ms
[40].
Field potential duration measurements
Although several approaches have claimed to be successful in
accurately determining the onset and offset of ECG [41–46], they
have limited utility in the MEA field potential analysis as the MEA
depolarisation and repolarisation phases may exhibit much more
diverse waveforms with narrow amplitude gradients and several
diverse morphological features: positive, negative, only upwards,
only downwards or biphasic waveforms. One source of variability
could be the three-dimensional CM aggregates used in MEA
analysis. These aggregates exhibit more variation in signal shape
between the recordings and between the different electrodes due to
their three-dimensional structure and spatial variability with
respect to the MEA electrodes. This constitutes a major challenge
in developing robust automated algorithms for the analysis of CM
MEA signals. Due to such inherent variability in geometry, the
onset and offset determined using our indigenously developed
automatic detection algorithms have been ambivalent. Another
possible cause for ambiguity could be due to differences in
perception. Different studies have shown that researchers have
chosen these fiducial points based on individual reasoning and
observation. For example, some studies have considered repolar-
isation wave peak as the offset whereas several other researchers
have chosen the absolute end of the repolarisation phase to
determine the FPD [17] [47] [48]. In order to overcome these
issues, the CardioMDA facilitates the use of operator’s discretion
to decide between automatic/manual determinations of the onset
and offset.
We investigated the reliability and efficiency of the CardioMDA
in determining the FPD of CMs by applying known hERG
potassium channel blocker E-4031 [41] to the human iPSC
derived CMs and comparing the results to the manual analysis. As
a result of hERG channel block, the FPD is prolonged due to
increasing concentration of the drug [15] [16]. The signals
recorded after every drug challenge were averaged and manually
annotated for onset and offset using our software. Concurrently,
the raw signal data for each drug concentration was analysed
manually and compared with the results obtained from the
averaged signal. Table 3 shows the comparison results between the
raw signal data and averaged data. The mean and standard
deviation (S.D.) of FPD from the raw signal data rises due to the
increasing E-4031 concentration. The FPD measurements ob-
tained from the averaged signal corresponded well with the raw
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signal measurements, indicating that the results from the
CardioMDA are consistent.
Despite having statistical information of the FPD prolongation,
the differences in FPD do not reveal either the dynamics of
different ion channels or the magnitude of response as a result of
drug treatment. To be able to better understand these changes in
the ion channels, we have incorporated an overlay chart, which
allows up to 10 different signals recorded under different drug
concentrations, to be plotted for visual comparison. Fig. 6 is an
example of the overlay chart, which depicts the effect of the hERG
blocker E-4031 used in our experiment. From Fig. 6, it can be
observed that the FPD and repolarisation wave peak is prolonged,
and the amplitude of the initial sodium spike and repolarisation
wave (which corresponds to the ECG T-wave) decreases as a result
of increasing E-4031 concentration.
The offset point of the field potential cycle is most substantial
when assessing the effect of cardiac ion channel blocking drugs as
the FPD correlates with the QT-interval in ECG [8] [9]. Although
most drugs have been shown to prolong the FPD [15] [16], some
drugs do not seem to have effect on the offset point of the field
potential cycle. Rather, the effect is concentrated on the initial
repolarisation wave phase as seen in the case of anti-arrhythmic
drug Sotalol (Fig. 7) and potassium channel IKs blocking drug
JNJ303 (Fig. 8). When analysing these types of signals manually, it
is hard to distinguish repolarisation wave prolongation for different
drug concentrations. With the CardioMDA overlay feature, these
acute changes in morphology can be observed. The prolongation
of the repolarisation wave due to increasing drug concentration
could be used to determine the relative QT-interval prolonging
effect of drugs on CMs.
Conclusion
CardioMDA has been shown to be suitable for analysing MEA
signals from human iPS cell derived CMs, which can be used in
the pre-clinical context for assessing the safety of new drugs or
screen candidate drugs in patient-specific cardiac disease model-
ling. Traditionally, the FPD is determined manually by examining
several field potential complexes from the raw data or averaging
determined number of field potentials [38]. Our solution is to use
cross correlation method to identify the representative field
potential complexes based on a pre-selected templates. These
methods enable automatic determination of single or multiple field
potential complexes to represent the data for further detailed
analysis and visualization. The accurate determination of onset
and offset for calculating FPD from raw signals is often tedious due
to noise. Moreover, manual data analysis has proven to be time-
consuming, work-demanding and the results are usually user
biased. Based on the template method, these discrepancies can be
overcome and it provides a means for reliable FPD analysis. Apart
from eliminating ambiguity in the results obtained manually, there
are several benefits with the use of CardioMDA. The software is
capable of screening large datasets when compared to manual
analysis and ensures increased work and time efficacy as only one
averaged signal representing each cardiac cell population needs to
be analysed. At present, we are not aware of any similar software
that is available in open source. As there is increased use of hPSC-
derived CMs for drug screening with MEA [15] [16] [49][50],
there is a significant demand for faster and consistent analysis
methods. We believe our software will provide a reliable means of
efficient and swift analysis for future studies.
Availability
The CardioMDA has been designed to facilitate the data
analysis of MEA recordings obtained from CM cell aggregates and
is available for registered users. Website for downloading the
program: www.biomeditech.fi/CardioMDA.
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